These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 12082305

  • 1. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
    Yamamoto S, Yamamoto T, Nojima Y, Umemori K, Phalen S, McMurray DN, Kuramoto E, Iho S, Takauji R, Sato Y, Yamada T, Ohara N, Matsumoto S, Goto Y, Matsuo K, Tokunaga T.
    Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
    [Abstract] [Full Text] [Related]

  • 2. [CpG motif and tuberculosis immunity].
    Yamamoto S.
    Kekkaku; 2010 Jun; 85(6):515-22. PubMed ID: 20662247
    [Abstract] [Full Text] [Related]

  • 3. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M, Akagawa K, Kobayashi K, Sugawara I, Kawakami K, Yamamoto S, Okada Z.
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM.
    Int Rev Immunol; 2006 Jan; 25(3-4):135-54. PubMed ID: 16818369
    [Abstract] [Full Text] [Related]

  • 5. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
    Klinman DM, Yamshchikov G, Ishigatsubo Y.
    J Immunol; 1997 Apr 15; 158(8):3635-9. PubMed ID: 9103425
    [Abstract] [Full Text] [Related]

  • 6. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.
    Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM.
    J Immunol; 1999 Feb 15; 162(4):2291-8. PubMed ID: 9973506
    [Abstract] [Full Text] [Related]

  • 7. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC.
    Int Immunopharmacol; 2006 Oct 15; 6(10):1586-96. PubMed ID: 16919831
    [Abstract] [Full Text] [Related]

  • 8. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex.
    Jones DE, Palmer JM, Burt AD, Walker C, Robe AJ, Kirby JA.
    Hepatology; 2002 Sep 15; 36(3):679-86. PubMed ID: 12198661
    [Abstract] [Full Text] [Related]

  • 9. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.
    Lobell A, Weissert R, Eltayeb S, Svanholm C, Olsson T, Wigzell H.
    J Immunol; 1999 Nov 01; 163(9):4754-62. PubMed ID: 10528174
    [Abstract] [Full Text] [Related]

  • 10. CpG motifs for optimization of DNA vaccines.
    Davis HL.
    Dev Biol (Basel); 2000 Nov 01; 104():165-9. PubMed ID: 11713816
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antitumor activity of cationic lipid complexed with immunostimulatory DNA.
    Rudginsky S, Siders W, Ingram L, Marshall J, Scheule R, Kaplan J.
    Mol Ther; 2001 Oct 01; 4(4):347-55. PubMed ID: 11592838
    [Abstract] [Full Text] [Related]

  • 13. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice.
    Obermeier F, Dunger N, Deml L, Herfarth H, Schölmerich J, Falk W.
    Eur J Immunol; 2002 Jul 01; 32(7):2084-92. PubMed ID: 12115630
    [Abstract] [Full Text] [Related]

  • 14. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.
    Krieg AM, Love-Homan L, Yi AK, Harty JT.
    J Immunol; 1998 Sep 01; 161(5):2428-34. PubMed ID: 9725240
    [Abstract] [Full Text] [Related]

  • 15. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.
    Lee KW, Jung J, Lee Y, Kim TY, Choi SY, Park J, Kim DS, Kwon HJ.
    Mol Immunol; 2006 May 01; 43(13):2107-18. PubMed ID: 16442622
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D.
    Methods Mol Med; 2006 May 01; 127():139-58. PubMed ID: 16988453
    [Abstract] [Full Text] [Related]

  • 17. Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs?
    Verfaillie T, Cox E, Goddeeris BM.
    Vet Immunol Immunopathol; 2005 Jan 10; 103(1-2):141-51. PubMed ID: 15626469
    [Abstract] [Full Text] [Related]

  • 18. Immunopharmacology of CpG DNA.
    Dalpke A, Zimmermann S, Heeg K.
    Biol Chem; 2002 Oct 10; 383(10):1491-500. PubMed ID: 12452427
    [Abstract] [Full Text] [Related]

  • 19. Immunostimulatory DNA as a vaccine adjuvant.
    Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD.
    Expert Rev Vaccines; 2007 Oct 10; 6(5):747-59. PubMed ID: 17931155
    [Abstract] [Full Text] [Related]

  • 20. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages.
    Shoda LK, Kegerreis KA, Suarez CE, Mwangi W, Knowles DP, Brown WC.
    J Leukoc Biol; 2001 Jul 10; 70(1):103-12. PubMed ID: 11435492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.